Ameriprise Financial Inc. Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Ameriprise Financial Inc. increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 14.6% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 271,805 shares of the specialty pharmaceutical company’s stock after purchasing an additional 34,586 shares during the quarter. Ameriprise Financial Inc. owned approximately 1.29% of ANI Pharmaceuticals worth $15,025,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of ANI Pharmaceuticals by 14.6% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,442 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 1,972 shares in the last quarter. Barclays PLC grew its holdings in ANI Pharmaceuticals by 1,681.2% in the 3rd quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company’s stock valued at $8,534,000 after buying an additional 135,003 shares in the last quarter. Franklin Resources Inc. grew its holdings in ANI Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock valued at $705,000 after buying an additional 691 shares in the last quarter. Victory Capital Management Inc. grew its holdings in ANI Pharmaceuticals by 6.6% in the 4th quarter. Victory Capital Management Inc. now owns 13,777 shares of the specialty pharmaceutical company’s stock valued at $762,000 after buying an additional 858 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in ANI Pharmaceuticals in the 4th quarter valued at $544,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the sale, the senior vice president now directly owns 68,624 shares in the company, valued at approximately $4,131,164.80. This trade represents a 1.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction on Monday, April 14th. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00. Following the transaction, the vice president now owns 80,145 shares of the company’s stock, valued at approximately $5,526,799.20. The trade was a 0.50% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 7,681 shares of company stock valued at $468,698. Corporate insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $59.99 on Friday. The stock has a market cap of $1.31 billion, a PE ratio of -109.07 and a beta of 0.56. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $77.00. The stock has a fifty day simple moving average of $66.91 and a 200-day simple moving average of $60.77.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $197.12 million for the quarter, compared to analyst estimates of $179.75 million. During the same quarter in the prior year, the company earned $0.82 EPS. ANI Pharmaceuticals’s revenue was up 43.4% on a year-over-year basis. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

ANIP has been the subject of several analyst reports. Guggenheim restated a “buy” rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 target price for the company. Truist Financial upped their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.